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Swith thoracoscopic lobectomy in other studies, anterolateral
thoracotomy was associated with more pain.9
In summary, this study suggests that the probability of
having no postoperative complications after lobectomy is
better with the thoracoscopic approach when compared
with the conventional thoracotomy approach. Thoracoscopic
lobectomy is also associated with a lower incidence of post-
operative AF and several other major complications. These
data suggest that the outcomes of patients with early-stage
NSCLC would be improved by using the thoracoscopic ap-
proach. The underlying factors responsible for this advantage
should be analyzed, which might be used to improve the
safety and outcomes of other thoracic procedures.
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Discussion
Dr John Mitchell (Denver, Colo). Dr Fullerton, members, and
guests, I would like to congratulate Dr Villamizar and his colleagues
on a very nice presentation and a well-written manuscript. In this
study you describe a lower incidence of postoperative complications
after thoracoscopic lobectomy compared with open lobectomy in
patients with lung cancer both in a retrospective analysis of a consec-
utive series of patients undergoing lobectomy and in a propensity-
matched analysis. The third portion that you presented today with
the propensity matching based on stage was not in the manuscript
I received, and therefore I will not address that per se.
I would guess that in the first overall analysis most of the differ-
ences in outcome could be explained by differences in the 2 patient
groups, such as the percentage undergoing induction therapy. In the
matched analysis there was a greater percentage of patients with no
complications, less AF, shorter hospital stays, and a shorter but
clinically insignificant chest tube duration.
Your findings frankly mirror my own observations with thoraco-
scopic lobectomy, but I have a few questions for you.
First, I was wondering if you could tell us what effect the loca-
tion or the type of lobectomy that you performed had on the com-
plication rates. Were right upper lobes associated with greater
complication rates than middle lobes or lower lobes or vice versa?
Dr Villamizar. We did not address that in our review. However,
both groups underwent the same percentage of right upper lobec-
tomy. In previous series we have not seen an association between
the location of the lobectomy and postoperative complications
and, in this particular case, with AF.
Dr Mitchell. My second question has to do with the stage. I was
going to ask you how the differences in stage between the 2
matched groups had an effect on the outcomes. At least in the
matched series of 153 patients each, a majority of the thoracoscop-
ies, not surprisingly, were done in patients with stage I disease.
Could you expound a little bit more on how the stage has an effect
on the results that you described today?
Dr Villamizar. When we did the propensity-matched analysis,
the idea was to have groups that were comparable in terms of base-
line characteristics. We did find in that first propensity-matched
analysis that the stage was different, and that is why we proceeded
to do another matched analysis, this time based on stage. From thatrgery c August 2009
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Slast matched analysis, it seems that the stage did not affect the in-
cidence of postoperative complications, and it was more the surgi-
cal approach that had a bigger effect.
Dr Mitchell. I had always thought that AF seen in conjunction
with lobectomy was due to manipulation of the pulmonary veins or
dissection at the hilum. These factors should have been the same
whether the procedure was done open or thoracoscopically, and
therefore how do you account for less AF in the thoracoscopic group?
Dr Villamizar. That is correct. In our institution the dissection is
similar whether we do it thoracoscopically or through a thoracot-
omy. It is unclear at this point what is causing the AF, but there
is some literature that supports the idea that in the open thoracot-
omy group there is a higher cytokine and inflammatory response
overall, as well as increasing white blood cell count. It is possible
that the cytokines are related to the presence of AF.
Dr Robert Cerfolio (Birmingham, Ala). Congratulations on an
outstanding paper that was very well presented. Can you tell me
your criteria for chest tube removal and why the patients undergo-
ing open lobectomies are in the hospital for 7 days and have chest
tube in for so long, 7 days? I believe this is what has artificially in-
flated the bad results in your open group. What do you use to take
the chest tube out?
Dr Villamizar. If the patient has drainage of less than 200 mL,
even on postoperative day 1, and the patient does not have an air
leak, we will remove the chest tube.
Dr Cerfolio. So you use a very low traditional number. You
have not increased that number to 300 or 400 or 450 mL, as we
have recently published is safe? Is that the thing that is keeping
the chest tube in longer in the open group versus the video-assisted
thoracoscopic surgery group?
Dr Villamizar. Those are the criteria that we use for postoper-
ative day 1 or 2. If the patient does not have a leak and the output
is greater than 200 mL but, let us say, less than 400 mL and the pa-
tient had a thoracoscopic approach, the chest tube would be re-
moved on postoperative day 2 anyway. The reason why there is
a difference between the 2 groups in removing the chest tube is be-
cause in the thoracotomy group the drainage from the chest tube
will be greater than 400 or 500 mL usually.
Dr Cerfolio. This answer shows why the open group did so
poorly in terms of length of stay.
Finally, what would you say to someone like me—and you can
go ahead and give me the business if you want, which is always
fun—who still prefers open lobectomy but sends my patient
home on the third or fourth day, most (ie, 99%) with their chest
tubes out, although some go home with their chest tubes in if
they have an air leak. I am very happy with a rib-sparing, nerve-
sparing, muscle-sparing thoracotomy, and in fact, I think it even
hurts less than my patients undergoing video-assisted thoraco-The Journal of Thoracic andscopic surgery. What would you say to me to convince me to start
doing more video-assisted thoracoscopic surgery lobectomies for
patients with cancer?
Dr Villamizar. We know that you have very good experience
with the thoracotomy approach, and your results are very good.
However, there is strong literature that supports the idea that the
thoracoscopic approach is related to a lower incidence of postoper-
ative complications and, in this study, AF. Even if you remove the
chest tube on the third day and send your patients home at the same
time that you would send home a patient undergoing a thoraco-
scopic approach, it is possible that the incidence of AF and other
complications would be reduced if you were using the thoraco-
scopic approach.
Dr Douglas Wood (Seattle, Wash). I just want to follow up on
Dr Cerfolio’s question. Most of the outcome variables that you
looked at were not affected by providers; however, the variable
of chest tube removal and the variable of hospital discharge are re-
lated to provider decisions. Can you comment on potential provider
biases that might exist in perceiving that patients can have chest
tubes removed earlier or that they can be discharged earlier if
they undergo thoracoscopy and how that might influence those out-
comes in ways that are not related to the procedure itself but are re-
lated to the bias of the providers?
Dr Villamizar. We have noticed over the years that even the
way that our surgeons approach postoperative recovery in the tho-
racotomy group is different based on the experience that we have
acquired with the thoracoscopic group. The surgeons used to re-
move chest tubes at a later day, but now what we see is that the chest
tube is removed at an earlier point, which is reflected in this study
by only a 1-day difference in the median between the 2 groups.
Again, this difference is mostly due to patients who have a larger
volume draining from the chest tube in the thoracotomy group.
Unidentified speaker. I have a quick question. Your study
shows that this operation can be done. The question is this: Should
it be done? At the American Thoracic Society, a paper was pre-
sented that showed there is a statistically significant lower number
of lymph nodes sampled with a video approach from a very high-
volume very well-respected cancer center. Did you look at the num-
ber of nodes harvested with each technique, and did you see any
differences in the pathologic result?
Dr Villamizar. We did not address this question in this study,
but our experience is that the number of nodes removed with the
thoracoscopic approach is the same or is not statistically different
from the number of nodes removed with thoracotomy. In previous
series other groups have also demonstrated this fact, as well as no
differences in overall survival between the 2 surgical techniques.
The survival is comparable or even better with the thoracoscopic
approach.Cardiovascular Surgery c Volume 138, Number 2 425
